PriceTargets.com logo

Immix Biopharma - IMMX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $22.86
  • Forecasted Upside: 91.93%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$11.91 As of 09/15/2026 11:47 AM ET
▼ -0.301 (-2.47%)

This chart shows the closing price for IMMX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immix Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMMX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMMX

Analyst Price Target is $22.86
▲ +91.93% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Immix Biopharma in the last 3 months. The average price target is $22.86, with a high forecast of $27.00 and a low forecast of $19.00. The average price target represents a 91.93% upside from the last price of $11.91.

This chart shows the closing price for IMMX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Immix Biopharma. This rating has held steady since March 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/16/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/15/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/14/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/15/2026MizuhoBoost TargetOutperform ➝ Outperform$15.00 ➝ $26.00
8/14/2026CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
8/11/2026Morgan StanleyLower TargetOverweight ➝ Overweight$20.00 ➝ $19.00
8/10/2026HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $25.00
7/22/2026Needham & Company LLCInitiated CoverageBuy$21.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/18/2026CitigroupInitiated CoverageBuy
6/18/2026Bank of AmericaInitiated CoverageBuy$27.00
6/17/2026Lifesci CapitalInitiated CoverageOutperform$19.00
5/22/2026HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/30/2026MizuhoBoost TargetOutperform ➝ Outperform$14.00 ➝ $15.00
3/27/2026Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$23.00
3/27/2026HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $15.00
3/25/2026Morgan StanleyInitiated CoverageOverweight$20.00
3/9/2026Citizens JmpInitiated CoverageOutperform$23.00
2/9/2026MizuhoInitiated CoverageOutperform$14.00
2/9/2026MizuhoInitiated CoverageOutperform$14.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/12/2025HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
8/25/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
6/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00
2/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
1/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
10/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/1/2024HC WainwrightInitiated CoverageBuy$7.00
8/14/2023Roth CapitalReiterated RatingBuy ➝ Buy$14.00
2/22/2023Roth CapitalReiterated RatingBuy
2/22/2023Roth CapitalInitiated CoverageBuy$14.00
10/17/2022ThinkEquityInitiated CoverageBuy
(Data available from 9/15/2021 forward)

News Sentiment Rating

1.15 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/16/2026
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Immix Biopharma logo
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $11.91
Low: $11.88
High: $12.63

50 Day Range

MA: $11.33
Low: $8.17
High: $14.47

52 Week Range

Now: $11.91
Low: $1.94
High: $15.10

Volume

228,378 shs

Average Volume

1,268,508 shs

Market Capitalization

$851.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Immix Biopharma?

The following sell-side analysts have issued research reports on Immix Biopharma in the last year: Bank of America Corporation, Citigroup Inc., Citizens Jmp, HC Wainwright, Lifesci Capital, Mizuho, Morgan Stanley, Needham & Company LLC, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for IMMX.

What is the current price target for Immix Biopharma?

0 Wall Street analysts have set twelve-month price targets for Immix Biopharma in the last year. Their average twelve-month price target is $21.29, suggesting a possible upside of 74.3%. Bank of America Corporation has the highest price target set, predicting IMMX will reach $27.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $15.00 for Immix Biopharma in the next year.
View the latest price targets for IMMX.

What is the current consensus analyst rating for Immix Biopharma?

Immix Biopharma currently has 1 sell rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IMMX.

What other companies compete with Immix Biopharma?

Other companies that are similar to Immix Biopharma include Amylyx Pharmaceuticals, Arcus Biosciences, GRAIL, Denali Therapeutics and AbCellera Biologics. Learn More about companies similar to Immix Biopharma.

How do I contact Immix Biopharma's investor relations team?

Immix Biopharma's physical mailing address is 11400 West Olympic Blvd., Suite 200, Los Angeles, CA, 90064. The company's listed phone number is 310-651-8041. The official website for Immix Biopharma is www.immixbio.com. Learn More about contacing Immix Biopharma investor relations.